Bladder Neoplasms Clinical Trial
Official title:
Intravesical Gemcitabine Therapy in Intermediate Risk Superficial Bladder Cancer: A Phase II Study With the Marker Lesion
| Verified date | June 2007 |
| Source | Eli Lilly and Company |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Italy: Ethics Committee |
| Study type | Interventional |
This is a phase II study where chemotherapy (gemcitabine) is given into the urinary bladder.
| Status | Completed |
| Enrollment | 8 |
| Est. completion date | August 2004 |
| Est. primary completion date | |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years to 80 Years |
| Eligibility |
Inclusion Criteria: - Superficial bladder cancer - No prior chemotherapy Exclusion Criteria: - Grade 3 tumors - Papillary tumors invading connective tissue - Significant urologic disease, possible interfering with intravesical therapy |
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Italy | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Bologna | |
| Italy | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Como | |
| Italy | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Genova | |
| Italy | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Padova | |
| Italy | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Palermo | |
| Italy | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Roma | |
| Italy | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Varese |
| Lead Sponsor | Collaborator |
|---|---|
| Eli Lilly and Company |
Italy,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | To evaluate the response rate | |||
| Secondary | To define the relapse free survival | |||
| Secondary | To assess toxicity profile |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00536588 -
A Safety and Tolerability Study of SCH 721015 in Patients With Transitional Cell Carcinoma of the Bladder (Study P03816)
|
Phase 1 | |
| Recruiting |
NCT00872495 -
Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer
|
||
| Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
| Completed |
NCT00406068 -
Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer
|
Phase 2/Phase 3 | |
| Completed |
NCT00077688 -
TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium
|
Phase 2 | |
| Completed |
NCT00462488 -
Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ
|
Phase 2 | |
| Completed |
NCT00001381 -
A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder
|
Phase 1 | |
| Terminated |
NCT00050687 -
Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT00343356 -
Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder
|
Phase 2 | |
| Completed |
NCT01090388 -
Bladder Cancer Patient-Reported Outcomes
|
N/A | |
| Completed |
NCT00141531 -
Phase II Trial of EOquin in High-risk Superficial Bladder Cancer
|
Phase 2 | |
| Completed |
NCT00315237 -
Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract
|
Phase 3 | |
| Completed |
NCT00393809 -
Safety and Proof of Concept Study of Intravesical DTA-H19 in Patients With Superficial Bladder Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT00101608 -
Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
|
Phase 2 | |
| Terminated |
NCT00191477 -
Instillation of Gemcitabine in Patients With Superficial Bladder Cancer
|
Phase 3 | |
| Recruiting |
NCT05072600 -
Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer
|
Phase 2 | |
| Completed |
NCT00963404 -
Image-Guided Tumorboost of Bladder Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT00109655 -
Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure
|
Phase 1 | |
| Completed |
NCT00188695 -
Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT00871754 -
Molecular Analysis Of Bladder Cancer
|